VEGF-A and ICAM-1 Gene Polymorphisms as Predictors of Clinical Outcome to First-Line Bevacizumab-Based Treatment in Metastatic Colorectal Cancer

Bevacizumab is used to treat metastatic colorectal cancer (mCRC). However, there are still no available predictors of clinical outcomes. We investigated selected single nucleotide polymorphisms (SNPs) in the genes involved in VEGF-dependent and -independent angiogenesis pathways and other major intr...

Descripción completa

Detalles Bibliográficos
Autores principales: Papachristos, Apostolos, Kemos, Polychronis, Katsila, Theodora, Panoilia, Eirini, Patrinos, George P., Kalofonos, Haralabos, Sivolapenko, Gregory B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6888109/
https://www.ncbi.nlm.nih.gov/pubmed/31752122
http://dx.doi.org/10.3390/ijms20225791

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6888109/
https://www.ncbi.nlm.nih.gov/pubmed/31752122
http://dx.doi.org/10.3390/ijms20225791

Ejemplares similares